Targeting CCR2/5 in the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.
Targeting CCR2/5 in the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.
Expert Opin Investig Drugs. 2020 Jan 17;:
Authors: Lefere S, Devisscher L, Tacke F
PMID: 31952447 [PubMed - as supplied by publisher]
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
More News: Alcoholism | Drugs & Pharmacology